Sensei Biotherapeutics, Inc. (SNSE)
NASDAQ: SNSE · Real-Time Price · USD
8.55
+0.62 (7.82%)
Sep 9, 2025, 12:11 PM - Market open
Sensei Biotherapeutics Employees
As of December 31, 2024, Sensei Biotherapeutics had 15 total employees, including 14 full-time and 1 part-time employees. The number of employees decreased by 13 or -46.43% compared to the previous year.
Employees
15
Change (1Y)
-13
Growth (1Y)
-46.43%
Revenue / Employee
n/a
Profits / Employee
-$1,788,200
Market Cap
10.78M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 15 | -13 | -46.43% |
Dec 31, 2023 | 28 | 0 | - |
Dec 31, 2022 | 28 | -28 | -50.00% |
Dec 31, 2021 | 56 | 24 | 75.00% |
Dec 31, 2020 | 32 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SNSE News
- 6 days ago - Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 5 weeks ago - Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025 - GlobeNewsWire
- 3 months ago - Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split - GlobeNewsWire
- 4 months ago - Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress - GlobeNewsWire
- 5 months ago - Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference - GlobeNewsWire
- 5 months ago - Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress - GlobeNewsWire
- 5 months ago - Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors - GlobeNewsWire